PHARMACY

Janssen gets FDA green light for new Invokana indication
Janssen's oral diabetes treatment is the first oral diabetes treatment to have an indication to reduce the risk of heart attack, stroke or cardiovascular death, the company said.
Cipla gets FDA OK for generic Valcyte
The FDA has approved Cipla's generic Valcyte, which had a market value of about $79 million.

FDA touts record-breaking number of October generic approvals

The Food and Drug Administration approved 110 generic drugs and tentatively approved 18 generic drugs for a total of 128 approval actions throughout the month of October.
Theravance Biopharma, Mylan get FDA approval for Yupelri

Yupelri is the first and only once-daily nebulized bronchodilator approved for the treatment of COPD, the companies said.
Lupin launches generic Mepron

Lupin is debuting a generic version of GlaxoSmithKline’s Mepron, which had a market value of about $119 million, according to IQVIA data.
Amneal, Lannett complete transition agreement for generic levothyroxine

Amneal’s agreement with Lannett accelerates the company's launch of the generic thyroid drug, levothyroxine.
Hikma, Vectura to develop generic versions of GSK’s Ellipta portfolio

Hikma and Vectura plan to develop generic versions of GSK's Ellipta portfolio, utilizing Vectura's proprietary "open-inhale-close" dry powder inhaler device.
Genoa Healthcare debuts 14 pharmacies

With the opening of 14 new pharmacies, Genoa Healthcare has a total of 437 pharmacies.
Cumberland Pharmaceuticals to acquire Theravance Biopharma’s Vibativ

Cumberland Pharmaceuticals is set to acquire Theravance Biopharma’s Vibativ, which is used to treat serious bacterial infections.
FDA approved clobazam oral film formulation

Sympazan is the first clobazam oral film formulation approved by the Food and Drug Administration, maker Aquestive Therapeutics said.